POTENSI INTERAKSI OBAT DENGAN OBAT PADA PASIEN DEWASA DENGAN PNEUMONIA
DOI:
https://doi.org/10.36465/jop.v4i2.746Keywords:
Interaksi obat, mayor, minor, moderat, odds ratioAbstract
Pneumonia merupakan infeksi yang disebabkan mikroorganisme yang ditandai dengan adanya inflamasi pada parenkim paru. Mayoritas pasien pneumonia yang di rawat di rumah sakit mendapatkan obat dalam jumlah lebih dari lima. Hal tersebut dapat meningkatkan risiko potensi interaksi obat. Interaksi obat merupakan salah satu penyebab adanya reaksi obat yang tidak dikehendaki. Tujuan dari penelitian ini adalah untuk mengidentifikasi potensi interaksi obat dengan obat serta mengetahui jumlah pasien yang mengalami potensi interaksi obat dengan obat dan risiko potensi interaksi obat dengan obat. Desain studi pada penelitian ini yaitu potong lintang dengan pengambilan data secara retrospektif. Pengambilan data diambil dari rekam medik pasien pneumonia di salah satu rumah sakit di Kota Bandung pada periode Januari-Desember 2018. Hasil didapatkan bahwa potensi interaksi obat yang dapat diidentifikasi sebesar 480 interaksi. Interaksi meliputi 261 interaksi mayor (54,38%), 214 interaksi moderat (44,58%), dan 5 interaksi minor (1,04%). Dari total 402 pasien, 48,51% pasien mengalami potensi interaksi obat dengan obat. Terdapat hubungan yang bermakna antara jumlah obat dengan potensi interaksi obat dengan obat (nilai-p < 0,05). Pasien yang mendapatkan > 6 obat memiliki risiko 10,1 kali lebih tinggi mengalami potensi interaksi obat dengan obat dibandingkan dengan yang mendapatkan < 6 obat (IK 95% 6,0-16,9).
References
Alves, C., Mendes, D. and Marques, F. B. (2019) ‘Fluoroquinolones and the risk of tendon injury: a systematic review and meta-analysis’, European journal of clinical pharmacology, 75(10), pp. 1431–1443.
Arabyat, R. M. et al. (2015) ‘Fluoroquinolone-associated tendon-rupture: a summary of reports in the Food and Drug Administration’s adverse event reporting system’, Expert opinion on drug safety, 14(11), pp. 1653–1660.
Asadi, L. et al. (2012) ‘Macrolide-based regimens and mortality in hospitalized patients with community-acquired pneumonia: a systematic review and meta-analysis.’, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 55(3), pp. 371–380. doi: 10.1093/cid/cis414.
Bucşa, C. et al. (2013) ‘How many potential drug–drug interactions cause adverse drug reactions in hospitalized patients?’, European journal of internal medicine, 24(1), pp. 27–33.
Cahyaningsih, I. and Wicaksono, W. A. (2020) ‘Penilaian Risiko Interaksi Obat pada Pasien dengan Diabetes Melitus Tipe 2’, Indonesian Journal of Clinical Pharmacy, 9(1), pp. 9–17.
Cai, M. et al. (2013) ‘Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia’, Immunobiology, 218(6), pp. 930–937.
Dechanont, S. et al. (2014) ‘Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis.’, Pharmacoepidemiology and drug safety, 23(5), pp. 489–497. doi: 10.1002/pds.3592.
Eccles, S. et al. (2014) ‘Diagnosis and management of community and hospital acquired pneumonia in adults: summary of NICE guidance’, Bmj, 349.
Feinstein, J. et al. (2015) ‘Potential Drug−Drug Interactions in Infant, Child, and Adolescent Patients in Children’s Hospitals’, Pediatrics, 135(1), p. e99 LP-e108. doi: 10.1542/peds.2014-2015.
Fitriani, S. W. et al. (2016) ‘Angka kejadian dan faktor yang memengaruhi potensi interaksi obat dengan obat pada pasien leukemia akut anak yang menjalani rawat inap’, Sari Pediatri, 18(2), pp. 129–136.
Gamble, J.-M. et al. (2014) ‘Medication transitions and polypharmacy in older adults following acute care.’, Therapeutics and clinical risk management, 10, pp. 189–196. doi: 10.2147/TCRM.S58707.
Gupta, D. et al. (2012) ‘Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations’, Lung India : official organ of Indian Chest Society, 29(Suppl 2), pp. S27–S62. doi: 10.4103/0970-2113.99248.
Jara, A. J., Zamora, M. A. and Skarmeta, A. F. (2014) ‘Drug identification and interaction checker based on IoT to minimize adverse drug reactions and improve drug compliance’, Personal and ubiquitous computing, 18(1), pp. 5–17.
Mackenzie, G. (2016) ‘The definition and classification of pneumonia.’, Pneumonia (Nathan Qld.), p. 14. doi: 10.1186/s41479-016-0012-z.
Mizokami, F. et al. (2012) ‘Polypharmacy With Common Diseases in Hospitalized Elderly Patients’, The American Journal of Geriatric Pharmacotherapy, 10(2), pp. 123–128. doi: https://doi.org/10.1016/j.amjopharm.2012.02.003.
Montastruc, J.-L. et al. (2019) ‘What is pharmacoepidemiology? Definition, methods, interest and clinical applications’, Therapies, 74(2), pp. 169–174.
Mousavi, S. and Ghanbari, G. (2017) ‘Potential drug-drug interactions among hospitalized patients in a developing country.’, Caspian journal of internal medicine, 8(4), pp. 282–288. doi: 10.22088/cjim.8.4.282.
Noor, S., Ismail, M. and Ali, Z. (2019) ‘Potential drug-drug interactions among pneumonia patients: do these matter in clinical perspectives?’, BMC Pharmacology and Toxicology, 20(1), pp. 1–16.
PDPI (2014) ‘Pneumonia komunitas: Pedoman diagnosis dan penatalaksanaan’, Edisi II. Jakarta: Badan Penerbit FKUI.
Radzikowska, E. et al. (2016) ‘Clarithromycin decreases IL-6 concentration in serum and BAL fluid in patients with cryptogenic organizing pneumonia’, Advances in Clinical and Experimental Medicine, 25(5), pp. 871–878.
Raslan, H. Y. et al. (2018) ‘Prevalence and Risk Factors of Potential Drug Interactions in Hospitalized Cardiovascular Patients Using Three Knowledge Bases’, Journal of Advances in Medical and Pharmaceutical Sciences, pp. 1–18.
Riaz, M. K. (2019) ‘Potential drug-drug interactions and strategies for their detection and prevention’, FARMACIA, 67(4), pp. 572–579.
Santoso, S. (2020) Panduan Lengkap SPSS 26. Elex Media Komputindo.
Şimşek, A. et al. (2019) ‘The importance of computerized drug interaction checker programs used in community pharmacies to avoid potential drug interactions: a preliminary study with clarithromycin’.
Viera, A. J. and Wouk, N. (2015) ‘Potassium disorders: hypokalemia and hyperkalemia’, American family physician, 92(6), pp. 487–495.
Wiersinga, W. J. et al. (2018) ‘Management of community-acquired pneumonia in adults: 2016 guideline update from the Dutch Working Party on Antibiotic Policy (SWAB) and Dutch Association of Chest Physicians (NVALT)’, Netherlands Journal of Medicine, 76(1), pp. 4–13.
Woodhead, M. et al. (2011) ‘Guidelines for the management of adult lower respiratory tract infections--full version.’, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 17 Suppl 6, pp. E1-59. doi: 10.1111/j.1469-0691.2011.03672.x
Zarogoulidis, P. et al. (2012) ‘Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases’, European journal of clinical pharmacology, 68(5), pp. 479–503.
Zhang, Q. et al. (2018) ‘N-acetylcysteine improves oxidative stress and inflammatory response in patients with community acquired pneumonia: A randomized controlled trial’, Medicine, 97(45), pp. e13087–e13087. doi: 10.1097/MD.0000000000013087.
